Morbilliform rashes due to erythromycin in a patient with herpes zoster infection
Keywords:
Erythromycin, morbilliform rashes, causality, severity, preventabilityAbstract
Erythromycin is a macrolide antibiotic active against many gram-positive infections and few gram-negative bacteria, as well as mycoplasmas, spirochetes, chlamydiae and rickettsiae. Dermatological reactions appear to be rare with erythromycin and mainly include maculopapular rashes, pruritus, urticaria, and angioedema, Reports of morbiliform rashes due to erythromycin are rare. We report a case of morbiliform reaction due to erythromycin in a patient suffering from herpes zoster with established causality, severity and preventability assessments. Upon development of the adverse drug reaction, we stopped the drug and managed the patient with systemic corticosteroids.References
Sweetman SC, ed. Martindale The Complete Drug Reference, 33rd edition. London: Pharmaceutical Press; 2002. ISBN 0-85369-499-0.
Ruef C, Krause M. Miscellaneous antibacterial drugs: lincomycins, macrolides, nitrofurantoin and polymyxins. In: Dukes MNG, Aronson JK, eds. Meyler’s Side Effects of Drugs, 14th edition. New York: Elsevier Science; 2000. p. 871-95.
Mehta DK, Martin J, Costello I et al. eds. BNF 50. London:: BMJ Publishing Group; 2005.
Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229-32.
Lau PM, Stewart K, Dooley MJ. Comment: hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2003; 37: 303-4.
Stern RS, Chosidow OM, Wintroub BU. Cutaneous drug reactions. In: Braunwald E, Fauci AS, Kasper DL et al. eds. Harrison’s Principles of Internal Medicine, 15th edn. New York: McGraw-Hill; 2001. p. 336-42
Magee P. Drug-induced skin disorders. In: Walker R, Edwards C, eds. Clinical Pharmacy and Therapeutics, 3rd edn. Phildelphia: Churchill Livingstone; 2003. p. 843-52.
Product Information: Akne-Mycin (R), erythromycin. Healthpoint, Ltd., Fort Worth, TX, 2000.
Pigatto PD, Riboldi A, Riva F et al. Fixed drug eruption to erythromycin. Acta Dermatol Venereol 1984; 3: 272-3.
11.Sullivan D, Csuka ME, Blanchard B. Erythromycin ethylsuccinate hepatotoxicity. JAMA 1980; 243: 1074.
Lee A, Thomas SHL. Adverse drug reactions. In: Walker R, Edwards C, eds. Clinical Pharmacy and Therapeutics, 3 rd edn. Philadelphia: Churchill Livingstone; 2000. p. 33-45.